Fig. 5From: Improved Anti-tumor Activity and Safety of Interleukin-13 Receptor Targeted Cytotoxin by Systemic Continuous Administration in Head and Neck Cancer Xenograft ModelAnti-tumor activity of IL-13 cytotoxin in large HN12 tumor models in mice. Male mice bearing SC large tumors (mean tumor size 87 ± 12 mm2) were treated with 100 µg/kg/day IV or 200 µg/kg/day CI of IL13-PE38QQR from day 13 to 19 (7 days); bars, SD (n = 7).Back to article page